Journal article
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers
HK Gan, S Parakh, FT Lee, NC Tebbutt, M Ameratunga, ST Lee, GJ O’Keefe, SJ Gong, C Vanrenen, J Caine, M Giovannetti, C Murone, FE Scott, N Guo, IJG Burvenich, C Paine, MJ Macri, M Kotsuma, G Senaldi, R Venhaus Show all
Investigational New Drugs | Published : 2022
Abstract
Ephrin type-A 2 (EphA2) is a transmembrane receptor expressed in epithelial cancers. We report on a phase I dose escalation and biodistribution study of DS-8895a, an anti-EphA2 antibody, in patients with advanced EphA2 positive cancers. DS-8895a was administered at 1, 3, 10 or 20 mg/kg every 2 weeks to determine safety, pharmacokinetics and anti-tumor efficacy. All patients underwent 89Zr trace-labelled infusion of DS-8895a (89Zr-DS-8995a) positron emission tomography imaging to determine the biodistribution of DS-8895a, and correlate findings with EphA2 expression, receptor saturation and response. Nine patients were enrolled on study. Of patients enrolled, seven patients received at least ..
View full abstractGrants
Awarded by Merck
Funding Acknowledgements
We acknowledge our funding sources including Daiichi-Sankyo for the support of the trial, Operational Infrastructure Support from the Victorian Government and the Clinical Trials Management group at Ludwig Cancer Research (New York), the support of SP (La Trobe University PhD Scholarship) and AMS (NHRMC Investigator Fellowship No. 1177837). This research was also undertaken using the Solid Target Laboratory, an ANSTO-Austin-LICR-ONJCRI Partnership.